Xavier Delavenne

List of Publications by Year
in descending order

74	1,648	304743	345221
papers	citations	22 h-index	36 g-index

80	80	80	2339
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tyrosine kinase inhibitors and direct oral anticoagulants: In vitro evaluation of drugâ€“drug interaction mediated by Pâ€glycoprotein. Fundamental and Clinical Pharmacology, 2022, 36, 860-868.	1.9	7
2	The impact of advanced age on anticoagulant therapy for acute venous thromboembolism. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 27-37.	3.3	2
3	Development of a Bayesian estimation tool to determine the optimal duration of apixaban discontinuation before a highâ€bleeding risk procedure. Fundamental and Clinical Pharmacology, 2022, , .	1.9	0
4	In Vitro Evaluation of P-gp-Mediated Drugâ€“Drug Interactions Using the RPTEC/TERT1 Human Renal Cell Model. European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47, 223-233.	1.6	3
5	Revised terminal halfâ€life of nonacog alfa as derived from extended sampling data: A realâ€world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis. Haemophilia, 2022, , .	2.1	3
6	TNF-Î± and IL-1Î² Exposure Modulates the Expression and Functionality of P-Glycoprotein in Intestinal and Renal Barriers. Molecular Pharmaceutics, 2022, 19, 2327-2334.	4.6	1
7	Pharmacobezoar After Venlafaxine and Oxazepam Overdose: How Pharmacokinetics Could Help?â€”A Grand Round. Therapeutic Drug Monitoring, 2021, 43, 143-145.	2.0	2
8	Severe Inflammation, Acute Kidney Injury, and Drugâ€“Drug Interaction: Triple Penalty for Prolonged Elimination of Apixaban in Patients With Coronavirus Disease 2019: A Grand Round. Therapeutic Drug Monitoring, 2021, 43, 455-458.	2.0	4
9	Inflammation Induces Changes in the Functional Expression of P-gp, BCRP, and MRP2: An Overview of Different Models and Consequences for Drug Disposition. Pharmaceutics, 2021, 13, 1544.	4.5	20
10	Pharmacokinetics of enoxaparin in COVID-19 critically ill patients. Thrombosis Research, 2021, 205, 120-127.	1.7	13
11	Functional, proteomic and phenotypic in vitro studies evidence podocyte injury after chronic exposure to heparin. Toxicology and Applied Pharmacology, 2021, 429, 115683.	2.8	1
12	Exposureâ€“Response Relationship of Tranexamic Acid in Cardiac Surgery. Anesthesiology, 2021, 134, 165-178.	2.5	37
13	Population pharmacokinetic model of cefazolin in total hip arthroplasty. Scientific Reports, 2021, 11, 19763.	3.3	5
14	In vitro assessment of Pâ€gp and BCRP transporterâ€mediated drugâ€“drug interactions of riociguat with direct oral anticoagulants. Fundamental and Clinical Pharmacology, 2020, 34, 109-119.	1.9	18
15	Efficacy and Safety of Direct Oral Anticoagulants in Kidney Transplantation: A Single-center Pilot Experience. Transplantation, 2020, 104, 2625-2631.	1.0	15
16	Accidental apixaban intoxication in a 23-month-old child: a case report. BMC Pediatrics, 2020, 20, 546.	1.7	4
17	Is the human model RPTEC/TERT1 a relevant model for assessing renal drug efflux?. Fundamental and Clinical Pharmacology, 2020, 35, 732-743.	1.9	4
18	Pharmacokinetic Model for Cefuroxime Dosing during Cardiac Surgery under Cardiopulmonary Bypass. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	2

#	Article	IF	Citations
19	Pharmacokinetics for haemophilia treaters: Meaning of PK parameters, interpretation pitfalls, and use in the clinic. Thrombosis Research, 2020, 192, 52-60.	1.7	13
20	Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients. Clinical Infectious Diseases, 2020, 71, 2227-2229.	5.8	80
21	Direct oral anticoagulants: Still too early for prime time after pulmonary endarteriectomy?. Journal of Thrombosis and Haemostasis, 2020, 18, 758-759.	3.8	1
22	A new paradigm for personalized prophylaxis for patients with severe haemophilia A. Haemophilia, 2020, 26, 228-235.	2.1	16
23	Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 148, 27-37.	4.3	6
24	Potential usefulness of activated charcoal (DOAC removeÂ®) for dRVVT testing in patients receiving Direct Oral AntiCoagulants. Thrombosis Research, 2019, 184, 86-91.	1.7	30
25	Effects of heparin and derivatives on podocytes: An in vitro functional and morphological evaluation. Journal of Cellular Physiology, 2019, 234, 15438-15449.	4.1	3
26	Direct oral anticoagulants are associated with limited damage of endothelial cells of the blood-brain barrier mediated by the thrombin/PAR-1 pathway. Brain Research, 2019, 1719, 57-63.	2.2	16
27	Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability. Journal of Thrombosis and Haemostasis, 2019, 17, 1670-1682.	3.8	24
28	Indications and potential pitfalls of anticoagulants in pulmonary hypertension: Would DOACs become a better option than VKAs?. Blood Reviews, 2019, 37, 100579.	5.7	16
29	Pharmacological characterization of the 3D MucilAirâ„¢ nasal model. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 139, 186-196.	4.3	39
30	Predicting the dose of vancomycin in ICU patients receiving different types of RRT therapy: a modelâ€based metaâ€analytic approach. British Journal of Clinical Pharmacology, 2019, 85, 1215-1226.	2.4	12
31	Dose tailoring of human cell lineâ€derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A. British Journal of Clinical Pharmacology, 2019, 85, 771-781.	2.4	11
32	The expected characteristics of an in vitro human Blood Brain Barrier model derived from cell lines, for studying how ABC transporters influence drug permeability. Journal of Drug Delivery Science and Technology, 2018, 45, 159-167.	3.0	5
33	Immunosuppression by a subconjunctival implant releasing dexamethasone in a rabbit model of penetrating keratoplasty. British Journal of Ophthalmology, 2018, 102, 692-699.	3.9	6
34	Pharmacological Characterization of the RPMI 2650 Model as a Relevant Tool for Assessing the Permeability of Intranasal Drugs. Molecular Pharmaceutics, 2018, 15, 2246-2256.	4.6	16
35	In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 519-525.	2.5	21
36	Individualized PKâ€based prophylaxis in severe haemophilia. Haemophilia, 2018, 24, 3-17.	2.1	28

#	Article	IF	Citations
37	Is RPMI 2650 a Suitable In Vitro Nasal Model for Drug Transport Studies?. European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43, 13-24.	1.6	23
38	Is tranexamic acid exposure related to blood loss in hip arthroplasty? A pharmacokineticâ€“pharmacodynamic study. British Journal of Clinical Pharmacology, 2018, 84, 310-319.	2.4	21
39	In Vitro Comparison of the Role of P-Glycoprotein and Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition. European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43, 183-191.	1.6	42
40	Assessment of HBEC-5i endothelial cell line cultivated in astrocyte conditioned medium as a human blood-brain barrier model for ABC drug transport studies. International Journal of Pharmaceutics, 2018, 551, 281-289.	5.2	38
41	Incidence and risk factors of major bleeding following major orthopaedic surgery with fondaparinux thromboprophylaxis. A timeâ€toâ€event analysis. British Journal of Clinical Pharmacology, 2018, 84, 2242-2251.	2.4	7
42	Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism. Pharmacological Research, 2017, 118, 33-42.	7.1	31
43	Effect of Activated Charcoal on Rivaroxaban Complex Absorption. Clinical Pharmacokinetics, 2017, 56, 793-801.	3.5	27
44	Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. Journal of Thrombosis and Haemostasis, 2017, 15, 273-283.	3.8	111
45	Pharmacokinetic/pharmacodynamic model for unfractionated heparin dosing during cardiopulmonary bypass. British Journal of Anaesthesia, 2017, 118, 705-712.	3.4	18
46	Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study. Thrombosis Research, 2017, 158, 126-133.	1.7	26
47	Glomerular filtration drug injury: In vitro evaluation of functional and morphological podocyte perturbations. Experimental Cell Research, 2017, 361, 300-307.	2.6	12
48	Intravenous Tranexamic Acid Bolus plus Infusion Is Not More Effective than a Single Bolus in Primary Hip Arthroplasty. Anesthesiology, 2017, 127, 413-422.	2.5	34
49	Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies. Pharmacological Research, 2017, 118, 19-32.	7.1	102
50	A new Strategy to Improve Drug Delivery to the Maxillary Sinuses: The Frequency Sweep Acoustic Airflow. Pharmaceutical Research, 2016, 33, 1074-1084.	3.5	14
51	Risk of Direct Oral Anticoagulant Bioaccumulation in Patients with Pulmonary Hypertension. Respiration, 2016, 91, 307-315.	2.6	18
52	A SAEM algorithm for fused lasso penalized NonLinear Mixed Effect Models: Application to group comparison in pharmacokinetics. Computational Statistics and Data Analysis, 2016, 95, 207-221.	1.2	5
53	In vitro and in vivo evaluation of drugâ€“drug interaction between dabigatran and proton pump inhibitors. Fundamental and Clinical Pharmacology, 2015, 29, 604-614.	1.9	31
54	Population pharmacokinetic model of free and total ropivacaine after transversus abdominis plane nerve block in patients undergoing liver resection. British Journal of Clinical Pharmacology, 2015, 80, 67-74.	2.4	15

#	Article	IF	Citations
55	Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit. CKJ: Clinical Kidney Journal, 2015, 8, 199-201.	2.9	8
56	PK evaluation of fondaparinux sodium for the treatment of thrombosis. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 269-277.	3.3	2
57	Quantification of total and unbound tranexamic acid in human plasma by ultrafiltration liquid chromatography/tandem mass spectrometry: Application to pharmacokinetic analysis. Journal of Pharmaceutical and Biomedical Analysis, 2014, 91, 32-36.	2.8	18
58	Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. Thrombosis and Haemostasis, 2014, 112, 240-248.	3.4	111
59	Investigation of drugâ€“drug interactions between clopidogrel and fluoxetine. Fundamental and Clinical Pharmacology, 2013, 27, 683-689.	1.9	20
60	Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: Application to pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2013, 78-79, 150-153.	2.8	49
61	Antithrombotics in pulmonary hypertension: more work needed before we turn to newer agents!. European Respiratory Journal, 2013, 41, 775-777.	6.7	10
62	Antipsychotics: A Real or Confounding Risk Factor for Venous Thromboembolism?. Pharmacopsychiatry, 2013, 46, 36-37.	3.3	19
63	A semiâ€mechanistic absorption model to evaluate drugâ€“drug interaction with dabigatran: application with clarithromycin. British Journal of Clinical Pharmacology, 2013, 76, 107-113.	2.4	60
64	Prevalence of poor biological response to clopidogrel. Thrombosis and Haemostasis, 2012, 107, 494-506.	3.4	81
65	A Pharmacokineticâ€“Pharmacodynamic Model for Predicting the Impact of CYP2C9 and VKORC1 Polymorphisms on Fluindione and Acenocoumarol During Induction Therapy. Clinical Pharmacokinetics, 2012, 51, 41-53.	3.5	26
66	Pharmacokinetics of fondaparinux 1.5 mg once daily in a real-world cohort of patients with renal impairment undergoing major orthopaedic surgery. European Journal of Clinical Pharmacology, 2012, 68, 1403-1410.	1.9	15
67	UPLC MS/MS assay for routine quantification of dabigatran â€“ A direct thrombin inhibitor â€“ In human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2012, 58, 152-156.	2.8	58
68	Mycophenolate sodium dosing in combination with tacrolimus: pharmacokinetic evaluation of a novel regimen in de novo tacrolimus-treated kidney transplant patients. Clinical Nephrology, 2012, 77, 425-431.	0.7	2
69	UPLC MS/MS method for quantification of mycophenolic acid and metabolites in human plasma: Application to pharmacokinetic study. Clinica Chimica Acta, 2011, 412, 59-65.	1.1	34
70	HPLC MS/MS method for quantification of meprobamate in human plasma: Application to 24/7 clinical toxicology. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 215-218.	2.3	6
71	Population pharmacokinetics of fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practice. Thrombosis and Haemostasis, 2010, 104, 252-260.	3.4	17
72	Ultraâ€performance LC MS/MS method for quantification of clopidogrel active metabolite. Journal of Separation Science, 2010, 33, 1968-1972.	2.5	21

#	Article	IF	Citations
73	Is there really a relationship between the plasma concentration of the active metabolite of clopidogrel and the results of platelet function tests?. Journal of Thrombosis and Haemostasis, 2010, 8, 2334-2338.	3.8	10
74	Investigation of PKâ€“PD drugâ€“drug interaction between acenocoumarol and amoxicillin plus clavulanic acid. Fundamental and Clinical Pharmacology, 2009, 23, 127-135.	1.9	12